title: The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
authors.forename: Jose
authors.initials: J
authors.lastname: de Leon
mesh_terms: D000483:Alleles; D000897:Anti-Ulcer Agents / Q000378:metabolism; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000378:metabolism*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics / Q000378:metabolism*; D000069445:Atomoxetine Hydrochloride; D015283:Citalopram / Q000378:metabolism; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism*; D014644:Genetic Variation; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics / Q000378:metabolism*; D009853:Omeprazole / Q000378:metabolism; D010597:Pharmacogenetics; D010641:Phenotype; D011437:Propylamines / Q000378:metabolism; D044469:Racial Groups
chemical_list: D000897:Anti-Ulcer Agents; D000929:Antidepressive Agents, Tricyclic; D011437:Propylamines; D015283:Citalopram; D000069445:Atomoxetine Hydrochloride; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D009853:Omeprazole